Elucidation of the binding sites of two novel Ru(II) complexes on bovine serum albumin.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Inorganic Biochemistry

• Publication date

  2016-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.jinorgbio.2016.02.034PMID 26970034
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anticancer Activities of Mononuclear Ruthenium(II) Coordination Complexes

  2015cited by this paper
• Interactions of arene ruthenium metallaprisms with human proteins.

  2015cited by this paper
• Suitability of TiO2 nanoparticles and prolate nanospheroids for laser desorption/ionization mass spectrometric characterization of bipyridine-containing complexes

  2015cited by this paper
• Insights into the Binding Sites of Organometallic Ruthenium Anticancer Compounds on Peptides Using Ultra-High Resolution Mass Spectrometry

  2014cited by this paper
• Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity

  2014cited by this paper
• Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.

  2014cited by this paper
• Exploring the interaction of cisplatin with β2-microglobulin: new insights into a chemotherapeutic drug

  2014cited by this paper
• New water-soluble ruthenium(II) terpyridine complexes for anticancer activity: synthesis, characterization, activation kinetics, and interaction with guanine derivatives.

  2014cited by this paper
• Cellular Transport Mechanisms of Cytotoxic Metallodrugs: An Overview beyond Cisplatin

  2014cited by this paper
• Monitoring metallofulfenamic–bovine serum albumin interactions: a novel method for metallodrug analysis

  2014cited by this paper
• Emerging protein targets for metal-based pharmaceutical agents: an update

  2013cited by this paper
• Colloidal TiO2 nanoparticles as substrates for M(S)ALDI mass spectrometry of transition metal complexes.

  2012cited by this paper
• Characterization of Pt-protein complexes by nHPLC-ESI-LTQ MS/MS using a gel-based bottom-up approach.

  2012cited by this paper
• Cytotoxicity of ruthenium(II) piano-stool complexes with imidazole-based PN ligands

  2012cited by this paper
• Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells.

  2012cited by this paper
• Inhibitory effect of platinum and ruthenium bipyridyl complexes on porcine pancreatic phospholipase A2.

  2011cited by this paper
• Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.

  2011cited by this paper
• A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core.

  2011cited by this paper
• Laser desorption and ionization time-of-flightversus matrix-assisted laser desorption and ionization time-of-flight mass spectrometry of and metal complexes.

  2011cited by this paper
• Terpyridine Platinum(II) Complexes Inhibit Cysteine Proteases by Binding to Active-site Cysteine

  2011cited by this paper
• Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MS.

  2010cited by this paper
• Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339

  2010cited by this paper
• Matrix-assisted laser desorption and ionisation time-of-flight mass spectrometry of Pt(II) and Pd(II) complexes

  2009cited by this paper
• Application of flavonoids - quercetin and rutin - as new matrices for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis of Pt(II) and Pd(II) complexes.

  2009cited by this paper
• Kinetics of albumin homocysteinylation measured with matrix-assisted laser/desorption ionization mass spectrometry versus with a radioactive tracer.

  2009cited by this paper
• Direct determination of the primary binding site of cisplatin on cytochrome c by mass spectrometry

  2009cited by this paper
• Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies.

  2008cited by this paper
• Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c

  2007cited by this paper
• ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme.

  2007cited by this paper
• Synthesis, characterization and reactivity of a novel ruthenium(II) complex containing polypyridyl ligand

  2007cited by this paper
• Mass spectrometric analysis of ubiquitin–platinum interactions of leading anticancer drugs: MALDI versus ESI

  2007cited by this paper
• Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

  2006cited by this paper
• Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy

  2004cited by this paper
• Solution‐ and Crystal‐Phase Covalent Modification of Lysozyme by a Purpose‐Designed Organoruthenium Complex. A MALDI‐TOF MS Study of its Metal Binding Sites

  2004cited by this paper
• Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin

  2003cited by this paper
• Relative binding strength of terpyridine model complexes under matrix-assisted laser desorption/ionization mass spectrometry conditions.

  2003cited by this paper
• Determination of drug binding sites to proteins by electrospray ionisation mass spectrometry: the interaction of cisplatin with transferrin.

  2002cited by this paper
• Fragmentation chemistry of [M + Cu]+ peptide ions containing an N-terminal arginine

  2000cited by this paper
• A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin.

  2000cited by this paper
• A Mass Spectral Study of the Binding of the Anticancer Drug Cisplatin to Ubiquitin

  1999cited by this paper
• Gas-Phase Coordination Properties of Zn2+, Cu2+, Ni2+, and Co2+ with Histidine-Containing Peptides

  1995cited by this paper
• Interaction of angiotensin peptides and zinc metal ions probed by electrospray ionization mass spectrometry

  1994cited by this paper
• Synthesis and properties of new DNA cleavage agents based on oxoruthenium(IV)

  1993cited by this paper
• New colorimetric cytotoxicity assay for anticancer-drug screening.

  1990cited by this paper
• Redox and spectral properties of monooxo polypyridyl complexes of ruthenium and osmium in aqueous media

  1984cited by this paper

• Heteroaryl-Terpyridine ruthenium(II) complexes in biocompatible ionic liquids: Synthesis, structural characterization, computational and biological evaluation

  2025cites this paper
• New ruthenium(II) complexes with quinone diimine and substituted bipyridine as inert ligands: synthesis, characterization, mechanism of action, DNA/HSA binding affinity and cytotoxic activity.

  2023cites this paper
• Metallomics and mass spectrometry for drug development: ICP-MS and MALDI TOF MS for assessment of protein-drug interactions

  2020cites this paper
• Redox and apoptotic potential of novel ruthenium complexes in the rat blood and heart.

  2020cites this paper
• Anti-adhesive action of novel ruthenium(II) chlorophenyl terpyridine complexes with a high affinity for double-stranded DNA: in vitro and in silico.

  2020cites this paper
• Chemistry and reactivity of ruthenium(II) complexes: DNA/protein binding mode and anticancer activity are related to the complex structure

  2019cites this paper
• Newly Synthesized Heteronuclear Ruthenium(II)/Ferrocene Complexes Suppress the Growth of Mammary Carcinoma in 4T1-Treated BALB/c Mice by Promoting Activation of Antitumor Immunity

  2018cites this paper
• Positive and negative nano-electrospray mass spectrometry of ruthenated serum albumin supported by docking studies: an integrated approach towards defining metallodrug binding sites on proteins.

  2018cites this paper
• New gold pincer-type complexes: synthesis, characterization, DNA binding studies and cytotoxicity.

  2018cites this paper
• New 4'-(4-chlorophenyl)-2,2':6',2″-terpyridine ruthenium(II) complexes: Synthesis, characterization, interaction with DNA/BSA and cytotoxicity studies.

  2017cites this paper
• Human topoisomerase inhibition and DNA/BSA binding of Ru(II)–SCAR complexes as potential anticancer candidates for oral application

  2017cites this paper
• High-Efficiency Microflow and Nanoflow Negative Electrospray Ionization of Peptides Induced by Gas-Phase Proton Transfer Reactions.

  2017cites this paper
• Interactions between proteins and Ru compounds of medicinal interest: A structural perspective

  2016cites this paper
• Highly water-soluble ruthenium(II) terpyridine coordination compounds form stable adducts with blood-borne metal transporting proteins

  2016influential citation